Equol (Isoflavandiol · Menopausal Support · DHT Inhibition)

Compound	Equol
Chemical class	Polyphenol — Isoflavandiol (Gut microbiome metabolite of daidzein)
CAS	531-95-3
Primary source	Intestinal microbial metabolism of daidzein (Glycine max, Pueraria lobata)
Key applications	Phytoestrogenic, menopausal support, DHT inhibition
Claim strength	Moderate
Typical form	S-Equol isolate (synthetic or fermentation-derived); equol-producing probiotic formulas
Buy from Herbuno	Request availability and bulk pricing →

Name origin: Equol was first identified in equine urine — horse urine — hence the name. It is the gut microbiome’s transformation product of daidzein via a reductive metabolic pathway. Traditional use: Equol itself has no traditional use as it is a metabolite rather than a plant compound. However, equol production capacity in Asian populations is significantly higher than Western populations (up to 60% vs. 30–50%), and this difference may partly explain lower menopausal symptom prevalence in East Asian women consuming high-soy diets. Research trajectory: Equol has attracted significant interest as a more potent phytoestrogen than daidzein (its precursor), with additional DHT-binding (5α-dihydrotestosterone) activity relevant to androgen-dependent conditions. Pre-formed S-equol supplementation has been studied to bypass the inter-individual variability in equol producer status. Commercial source: S-Equol is commercially available from specialist suppliers via soy fermentation or semi-synthesis from daidzein. Contact Herbuno for availability assessment.

---

Evidence for Equol Applications

Menopausal symptom management: S-Equol (the biologically active enantiomer) at 10–40 mg/day has been studied in Japanese and Western menopausal women, showing significant hot flush reduction in multiple RCTs. Effect is stronger than equivalent daidzein doses, consistent with equol’s higher ERβ affinity. The Japanese Equol Study and subsequent trials provide moderate RCT support. Claim strength: Moderate.

DHT inhibition and androgenic alopecia: Equol binds DHT directly (non-competitively), reducing its bioavailability to the androgen receptor. This is a unique mechanism among phytoestrogens — distinct from 5α-reductase inhibition. Human studies with S-equol show modest improvements in androgenic alopecia and reduction in DHT-related skin conditions. Claim strength: Moderate.

Bone density and cardiovascular: S-Equol RCTs show bone density preservation in postmenopausal women and improvements in arterial stiffness and lipid profiles. These effects are consistent with its potent ERβ agonism and are better supported than equivalent effects from daidzein itself. Claim strength: Moderate.

---

Dosage & Formulator Specification

Clinical dose range for S-equol: 10–40 mg/day of the S-enantiomer. Products used in Japanese RCTs (Equelle®) contain 10 mg S-equol per tablet, taken 2–4 times daily. The R-enantiomer (R-equol) is biologically less active; specify S-equol when sourcing.

S-Equol can be produced via: (1) soy fermentation using equol-producing bacteria (Lactococcus sp. 20-92 and related strains); (2) semi-synthesis from daidzein. Both routes are commercially established at small scale. Herbuno Contact Herbuno for S-equol; contact for availability assessment.

Alternative approach for formulators: equol-promoting probiotic strains (Lactobacillus acidophilus, Bifidobacterium spp.) combined with daidzein may enhance endogenous equol production in some non-producers, though the response rate remains variable and unstudied in all populations.

---

Frequently Asked Questions — Equol

What is the difference between S-equol and R-equol?
Equol has a chiral centre producing two enantiomers. S-Equol (also called (S)-(−)-equol) is the form produced by gut bacteria and present in human plasma and urine after daidzein consumption. R-Equol can be produced synthetically but has lower ERβ affinity and biological activity. All clinical research and commercial equol products use S-equol specifically.

Can I take a probiotic to become an equol producer?
Research suggests equol producer status is largely determined by specific gut bacterial populations. Some intervention studies have shown increased equol production after specific probiotic supplementation, but reproducibility is limited. The most reliable approach for consistent equol exposure is direct S-equol supplementation rather than attempting microbiome modulation.

Is equol safer than pharmaceutical HRT for menopausal symptoms?
Equol is not a substitute for pharmaceutical HRT in severe menopausal symptoms or osteoporosis management. Its estrogenic potency is substantially lower than pharmaceutical oestrogens. For mild-to-moderate hot flushes in women preferring non-pharmaceutical options, S-equol supplementation has moderate clinical support with a favourable safety profile in short-to-medium term RCTs.

Is equol relevant for men’s health formulations?
Yes. DHT binding by equol provides a mechanism for androgenic alopecia management and benign prostatic hyperplasia (BPH) support that is distinct from 5α-reductase inhibitors. Small human studies in men show reduced DHT levels with S-equol supplementation. This is an underexplored application with meaningful mechanistic support.

---

Claim-strength scale – High = multiple human RCTs; Moderate = limited trials or strong preclinical convergence; Emerging = early-stage lab or animal data.

← HerbIQ Compound Index · HerbIQ P02: Extraction · HerbIQ P03: Delivery